Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Profit After Tax (2016 - 2025)

Moleculin Biotech's Profit After Tax history spans 10 years, with the latest figure at $15.6 million for Q4 2025.

  • Quarterly results put Profit After Tax at $15.6 million for Q4 2025, up 336.21% from a year ago — trailing twelve months through Dec 2025 was -$33.6 million (down 28.84% YoY), and the annual figure for FY2025 was -$33.6 million, down 28.84%.
  • Profit After Tax for Q4 2025 was $15.6 million at Moleculin Biotech, up from -$25.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $15.6 million in Q4 2025 to a low of -$25.4 million in Q3 2025.
  • The 5-year median for Profit After Tax is -$6.5 million (2024), against an average of -$6.7 million.
  • The sharpest move saw Profit After Tax tumbled 267.66% in 2021, then skyrocketed 336.21% in 2025.
  • Year by year, Profit After Tax stood at -$2.8 million in 2021, then plummeted by 141.79% to -$6.8 million in 2022, then tumbled by 51.68% to -$10.3 million in 2023, then skyrocketed by 35.88% to -$6.6 million in 2024, then skyrocketed by 336.21% to $15.6 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at $15.6 million, -$25.4 million, and -$17.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.